Lamictal

Lamotrigine, the active ingredient in Lamictal, is a sodium channel blocker presented as an oral tablet for oral use. It treats epilepsy and bipolar disorder in adults and children as indicated.

GNH USA supplies Lamictal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lamotrigine is used to manage neurological and mood‑stabilising conditions by modulating neuronal excitability.

Epilepsy: reduces seizure frequency and severity in focal and generalized seizures. Bipolar disorder: stabilises mood and decreases the risk of depressive episodes in patients with bipolar I or II. Partial seizures: helps control focal onset seizures with or without secondary generalisation.

Lamotrigine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dizziness or light‑headedness - Headache - Nausea or gastrointestinal upset - Skin rash or itching - Insomnia or sleep disturbances - Blurred vision

Serious or Rare Side Effects: - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Severe skin reactions such as drug reaction with eosinophilia and systemic symptoms (DRESS) - Blood dyscrasias including agranulocytosis or aplastic anaemia - Hepatic failure or significant liver enzyme elevations - Suicidal thoughts or behaviour

When prescribing lamotrigine, clinicians should consider several safety measures.

Monitor skin reactions: discontinue immediately if severe rash develops. Adjust dose with enzyme inducers: increase lamotrigine dose when co‑administered with carbamazepine, phenytoin or phenobarbital. Avoid abrupt discontinuation: taper gradually to reduce seizure risk. Use caution in hepatic impairment: dose may need adjustment. Store at room temperature: keep in the original pack, protect from moisture and light.

Lamotrigine interacts with several medicines that can alter its concentration or increase toxicity.

Major Interactions (Avoid): - Valproic acid: markedly increases lamotrigine levels and risk of severe skin reactions. - Carbamazepine: reduces lamotrigine plasma concentration, potentially decreasing efficacy. - Phenytoin: lowers lamotrigine levels, requiring dose adjustment. - Phenobarbital: decreases lamotrigine exposure, may necessitate higher dosing.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may reduce lamotrigine levels, monitor seizure control. - Selective serotonin reuptake inhibitors (SSRIs): additive central nervous system effects possible. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): rare reports of enhanced skin reactions.